ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1571

How Substantive Is Heart Rate Variability As a Predictor of Anti-TNF Treatment Outcome for Inflammatory Arthritis?

Andrew Holman1 and Edmund Ng2, 1Inmedix, Normandy Park, WA, 2Statistical Thinking, Seattle, WA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Autonomic disorders, Biologic agents, biomarkers and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

As rheumatologists search for new targets to improve immunosuppressive outcomes, the autonomic nervous system (ANS) as a co-factor in autoimmune disease expression has gained interest.  At ACR 2014, heart rate variability (HRV), an accepted assessment of ANS state, was described as a biomarker in SLE.  At ACR 2008, HRV predicted biologic treatment outcome for inflammatory arthritis in a 52-week, double-blind, prospective study1.  But, how worthy is HRV as a metric with pathophysiologic and even therapeutic impact?

Methods:

An in depth, post hoc analysis of the clinical study that established proprietary HRV (Omegawave Ltd, Espoo, Finland) as a predictor of biologic treatment outcome for inflammatory arthritis was conducted.1 To further evaluate the performance of HRV measures in predicting ACR outcomes, receiver operating characteristic (ROC) analysis have been carried out. Area under the ROC curve (AUC) was calculated and the ROC curve was plotted for each of the HRV measures. Youden index was used to find the optimal cutoff at which the sensitivity and specificity were maximized. Relative risk (RR) of the ACR response at the optimal cutoff was also calculated.

Results:

Thirty-three patients (25 rheumatoid and 8 psoriatic arthritis by ACR criteria) were included in the analysis.1 All HRV measures (parasympathetic, sympathetic, tension index, total power) achieved better prediction with increasing duration of anti-TNF therapy as measured by the AUC.  The HRV measures provided moderate to high AUC values at week 26 and week 52 for ACR20/50/70 (range: 0.631 to 0.926). ROC AUC (95% CI) was most optimal for parasympathetic and log tension index to predict ACR70 response at 52 weeks at 0.926 (0.834, 1.000) and 0.918 (0.824, 1.000), respectively.  At the optimal cutoff, sensitivity and specificity for the parasympathetic HRV measure to predict ACR70 at 52 weeks were 100% and 88.5%, respectively, and for the tension index, 100.0% and 84.6%, respectively. RR for all HRV measures at optimal cutoffs for ACR20/50/70 at 26 and 52 weeks ranged from 2.23 to infinity (all p-values < 0.05). Patients with parasympathetic > the optimal cutoff (0.17) were 16 times (RR 95% CI: 2.22 to 115.14) more likely to achieve ACR70 at 52 weeks than patients with parasympathetic ≤ the optimal cutoff (p-value < 0.001).

Conclusion:

 Expanded statistical analyses of the referenced study further supports HRV as substantively impactful of prediction of anti-TNF biologic treatment outcome of inflammatory arthritis.  These findings may encourage study in other diseases, with non-anti-TNF immunosuppressive regimens; expand elucidation of ANS immunomodulatory mechanisms that impact autoimmune disease expression and treatment response; and target the ANS as a prolific source of new therapeutics able to enhance immunosuppressive regimens.

 

  1. Autonomic Neurosci Basic Clinical 2008;143:58-67.

 


Disclosure: A. Holman, Inmedix, 4; E. Ng, Inmedix, 5.

To cite this abstract in AMA style:

Holman A, Ng E. How Substantive Is Heart Rate Variability As a Predictor of Anti-TNF Treatment Outcome for Inflammatory Arthritis? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/how-substantive-is-heart-rate-variability-as-a-predictor-of-anti-tnf-treatment-outcome-for-inflammatory-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/how-substantive-is-heart-rate-variability-as-a-predictor-of-anti-tnf-treatment-outcome-for-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology